528 related articles for article (PubMed ID: 16465663)
1. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
2. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation.
Koolwijk P; Miltenburg AM; van Erck MG; Oudshoorn M; Niedbala MJ; Breedveld FC; van Hinsbergh VW
J Rheumatol; 1995 Mar; 22(3):385-93. PubMed ID: 7783051
[TBL] [Abstract][Full Text] [Related]
3. Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis.
Tang YL; Zhu GQ; Hu L; Zheng M; Zhang JY; Shi ZD; Liang XH
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr; 109(4):541-7. PubMed ID: 20185343
[TBL] [Abstract][Full Text] [Related]
4. [Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluids from patients with rheumatoid arthritis and osteoarthritis].
Gotoh H; Yamada H; Yoshihara Y; Kikuchi T; Obata K; Shinmei M
Ryumachi; 1997 Feb; 37(1):3-8. PubMed ID: 9128417
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Li TJ; Lu KH
J Rheumatol; 2007 Apr; 34(4):785-93. PubMed ID: 17299841
[TBL] [Abstract][Full Text] [Related]
6. Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.
Diehl P; Hantke B; Hennig M; Tschesche H; Mittelmeier W; Schmitt M; Muehlenweg B
Int J Mol Med; 2004 May; 13(5):711-5. PubMed ID: 15067375
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
8. Clinical correlation with the PA/plasmin system in septic arthritis of the knee.
Hsieh YS; Yang SF; Lue KH; Lu KH
Clin Orthop Relat Res; 2006 Jun; 447():172-8. PubMed ID: 16505706
[TBL] [Abstract][Full Text] [Related]
9. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Lu KH
J Orthop Res; 2008 Apr; 26(4):475-84. PubMed ID: 17975844
[TBL] [Abstract][Full Text] [Related]
10. Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans.
Yang SF; Hsieh YS; Lue KH; Chu SC; Chang IC; Lu KH
Clin Biochem; 2008 Jan; 41(1-2):109-16. PubMed ID: 17996201
[TBL] [Abstract][Full Text] [Related]
11. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
12. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis.
Nonaka T; Kikuchi H; Ikeda T; Okamoto Y; Hamanishi C; Tanaka S
J Rheumatol; 2000 Apr; 27(4):997-1004. PubMed ID: 10782829
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
16. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
17. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
19. Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells.
Bruse C; Guan Y; Carlberg M; Carlström K; Bergqvist A
Fertil Steril; 2005 Apr; 83 Suppl 1():1155-60. PubMed ID: 15831288
[TBL] [Abstract][Full Text] [Related]
20. Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process.
Fibbi G; Serni U; Matucci A; Mannoni A; Pucci M; Anichini E; Del Rosso M
J Rheumatol; 1994 Dec; 21(12):2322-8. PubMed ID: 7699636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]